Trials / Terminated
TerminatedNCT04461886
A Long-term Study of NPC-12G Gel in Neurofibromatosis Type I
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- Nobelpharma · Industry
- Sex
- All
- Age
- 3 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this tria is to evaluate the safety and efficacy of long-term treatment with NPC-12G gel to patients with neurofibromatosis type I.
Detailed description
A Phase 3, open-label, uncontrolled, multicenter study to evaluate the safety and efficacy of long-term treatment with NPC-12G gel for patients with neurofibromatosis type I. Patients who meet all entry criteria for this trial apply NPC-12G gel twice a day for 52 weeks or more. Approximately 100 eligible patients will be enrolled.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NPC-12G gel | NPC-12G gel is containing 0.2% Sirolimus |
Timeline
- Start date
- 2020-07-08
- Primary completion
- 2021-12-07
- Completion
- 2021-12-07
- First posted
- 2020-07-08
- Last updated
- 2022-05-24
Locations
4 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT04461886. Inclusion in this directory is not an endorsement.